BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
They had an improvement in event-free survival, but they also had an improvement in overall survival. And that's so important for our patients because We've struggled to show an overall survival benefit in the perioperative setting. So we can be really critical about this trial, the way that they over-treated patients, but there was an overall survival benefit.
0
💬
0
Comments
Log in to comment.
There are no comments yet.